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To counter the development of salt-sensitive hypertension, multiple brain
G-protein-coupled receptor (GPCR) systems are activated to facilitate
sympathoinhibition, sodium homeostasis, and normotension. Currently there is a paucity
of knowledge regarding the role of down-stream GPCR-activated Gα-subunit proteins in
these critically important physiological regulatory responses required for long-term blood
pressure regulation. We have determined that brain Gαi2-proteins mediate natriuretic
and sympathoinhibitory responses produced by acute pharmacological (exogenous
central nociceptin/orphanin FQ receptor (NOP) and α2-adrenoceptor activation) and
physiological challenges to sodium homeostasis (intravenous volume expansion
and 1M sodium load) in conscious Sprague–Dawley rats. We have demonstrated
that in salt-resistant rat phenotypes, high dietary salt intake evokes site-specific up-
regulation of hypothalamic paraventricular nucleus (PVN) Gαi2-proteins. Further, we
established that PVN Gαi2 protein up-regulation prevents the development of renal
nerve-dependent sympathetically mediated salt-sensitive hypertension in Sprague–
Dawley and Dahl salt-resistant rats. Additionally, failure to up-regulate PVN Gαi2 proteins
during high salt-intake contributes to the pathophysiology of Dahl salt-sensitive (DSS)
hypertension. Collectively, our data demonstrate that brain, and likely PVN specific, Gαi2
protein pathways represent a central molecular pathway mediating sympathoinhibitory
renal-nerve dependent responses evoked to maintain sodium homeostasis and a
salt-resistant phenotype. Further, impairment of this endogenous “anti-hypertensive”
mechanism contributes to the pathophysiology of salt-sensitive hypertension.
Keywords: central Gαi2 proteins, blood pressure regulation, central G-protein coupled receptors, renal
sympathetic nerves, sympathetic nervous system, salt-sensitive hypertension, sodium homeostasis
Selectivity of Central Gα Proteins
G-proteins are a family of heterotrimeric proteins composed of α, β, and γ subunits. Following
ligand binding at a transmembrane G-protein coupled receptor (GPCR), signal transduction
is initiated by α-subunit mediated exchange of GDP for GTP and the dissociation into
activated α and βγ complexes that initiate downstream signal transduction to ultimately evoke
Abbreviations: AVP, vasopressin; CNS, central nervous system; DSR, Dahl salt-resistant; DSS, Dahl salt-sensitive; GPCR,
G-protein coupled receptor; i.c.v., intracerebroventricular; PVN, paraventricular nucleus; M, molar; NE, norepinephrine;
N/OFQ, nociceptin/orphanin FQ; NOP, nociceptin/orphanin FQ receptor; SD, Sprague–Dawley; VE, volume expansion.
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a biological response. This review is focused on delineating the
central actions of Gα proteins in cardiovascular and fluid and
electrolyte homeostasis. There are four major subtypes of Gα
proteins, Gαi/o, Gαs, Gαz, and Gαq (Figure 1), discussed in this
review, with a subsequent focus on Gαi2 proteins. The Gαi/o
and Gαz classes of Gα proteins principally inhibit adenylate
cyclase, thereby resulting in reduced cAMP levels. Additionally,
via associated βγ subunits Gαi/o proteins also activate potassium
channels. In contrast, Gαs proteins stimulate the activity of
adenylate cyclase to drive increased cAMP production. The final
subtype investigated in these studies, Gαq, does not impact cAMP
levels, and instead activates phospholipase C (PLC), resulting
in increased levels of intracellular inositol triphosphate (IP3)
and modulation of calcium release. It has been demonstrated in
cell culture systems that selective recruitment and/or availability
of Gα-subunit proteins plays a critical role in determining the
intracellular signaling responses to GPCR activation following
ligand binding (Nasman et al., 2001). The specific intracellular
actions evoked by selective action of individual Gα proteins has
been elegantly elucidated, in part, via studies conducted on the
nociceptin/orphanin FQ receptor (NOP). Activation of the NOP
GPCR results in signal transduction via Gαi1−3, Gαo, Gαz, and
Gαq proteins to initiate multiple cellular responses, including
activation of potassium channels and inhibition of calcium
channels, adenylyl cyclase, and MAPK phosphorylation—all of
which modulate neurotransmitter release and neuronal activity
(Reinscheid et al., 1995; Chan et al., 1998; Hawes et al., 1998;
Jeong and Ikeda, 1998; Yung et al., 1999; Tso and Wong, 2006).
In vitro studies on the α2-adrenoceptor, an extensively studied
key GPCR in cardiovascular regulation, have demonstrated signal
transduction via Gαi1−3, Gαo, Gαs, Gαz, and Gαq subunit
proteins which principally modulate adenylate cyclase activity
(Remaury et al., 1993; Nasman et al., 2001; Hein, 2006). However,
despite the elucidation of signal transduction pathways in vitro
for the NOP and α2-adrenoceptor (among others), there are
essentially no data at present correlating intracellular Gα protein
pathways to the physiological responses elicited by central GPCR
activation in vivo.
Brain Gα Proteins and Pharmacological
GPCR Activation
To investigate the potential of selective physiological actions
of central Gα-proteins following ligand binding at a GPCR
in vivo, we elected to use the highly selective GPCR agonist
nociceptin/orphanin FQ (N/OFQ) (Reinscheid et al., 1995; Calo
et al., 2005; Krowicki and Kapusta, 2006). N/OFQ, an opioid-like
peptide, produces highly reproducible cardiovascular depressor
and diuretic responses when administered centrally to conscious
rats via actions on the NOP receptor (Kapusta et al., 1997,
1999; Kapusta and Kenigs, 1999; Kakiya et al., 2000). Prior
in vitro studies suggested that central NOP receptors signal
through Gαi1, Gαi2, Gαi3 (Hawes et al., 1998), GαoA,B (Tso
and Wong, 2006), Gαz (Chan et al., 1998; Jeong and Ikeda,
1998), and Gαq (Yung et al., 1999) transduction pathways.
We therefore examined how inhibition of central Gαi/Gαo
proteins via pertussis toxin (Katada and Ui, 1982; Gullapalli
and Ramarao, 2002) or targeted selective down-regulation of
central Gαz or Gαq proteins via intracerebroventricular (i.c.v.)
oligodeoxynucleotide (ODN) pre-treatment (Rossi et al., 1995;
Standifer et al., 1996; Silva et al., 2000; Hadjimarkou et al., 2002)
impacted the characteristic cardiovascular, renal excretory, and
plasma vasopressin (AVP) responses to i.c.v. injection of N/OFQ
in conscious Sprague–Dawley rats. In control saline vehicle
or scrambled ODN pre-treatment groups, i.c.v. administration
of N/OFQ evoked bradycardia, hypotension, and diuresis. The
hypotension and bradycardia, but not diuresis, to N/OFQ was
abolished in pertussis toxin-pretreated rats in which the actions
of brain Gαi/Gαo proteins were inhibited. In contrast, i.c.v.
ODN pretreatment, which significantly and specifically down-
regulated central Gαz or Gαq protein expression as previously
reported (Rossi et al., 1995; Standifer et al., 1996; Silva et al.,
2000; Hadjimarkou et al., 2002) had a significant effect on the
diuresis to central N/OFQ without impacting the cardiovascular
responses. Owing to the known role of N/OFQ in suppressing
AVP release, reducing water reabsorption in the collecting ducts
of the kidneys and promoting diuresis, we determined that
the effects of central Gαz or Gαq down-regulation on N/OFQ
diuresis were mediated by blunting (Gαz) or augmenting (Gαq)
N/OFQ evoked suppression of AVP release (Wainford et al.,
2008). These studies demonstrate that in conscious Sprague–
Dawley rats the GPCR ligand N/OFQ acts centrally via the NOP
receptor to activate individual Gα protein signaling pathways
that control cardiovascular (Gαi/Gαo) vs. renal excretory (Gαz
or Gαq) function.
Extending our finding that central Gαz/Gαq protein pathways
play a pivotal role in modulating (inhibiting vs. stimulating,
respectively) AVP release and thereby diuresis to central N/OFQ
(Wainford et al., 2008), we examined the role of brain Gαz/Gαq
proteins in the regulation of AVP during a physiological
challenge. During high salt intake, Dahl salt-sensitive (DSS) rats
exhibit elevated plasma AVP (Bayorh et al., 1998; Gunnet et al.,
2008). In contrast, in salt-resistant rat phenotypes [i.e., Sprague–
Dawley (SD) and Dahl salt-resistant (DSR) rats], increased
dietary salt intake does not alter circulating AVP levels (Serino
et al., 2001; Wainford and Kapusta, 2009). A key finding of these
investigations is that in response to a high salt diet, SD and DSR
rats down-regulate Gαq protein levels within the hypothalamic
PVN, a major central site involved in AVP synthesis and release
(Landgraf et al., 1990; Nielsen et al., 1993; Grindstaff and
Cunningham, 2001). This site-specific down-regulation of PVN
Gαq proteins was correlated with the ability of SD and DSR rats
to maintain unchanged plasma AVP levels and fluid/electrolyte
balance in the face of a high salt challenge (Wainford and
Kapusta, 2010). In contrast, DSS rats do not exhibit such site-
specific down-regulation of Gαq proteins, which may contribute
to excess AVP release in this rat phenotype. Owing to the impact
of PVN Gαq proteins on the regulation of AVP release, we
speculate that within the PVN, the changes in Gαq protein
expression are predominantly localized to the magnocellular
neurons. Of physiological relevance, ODN-mediated down-
regulation of brain Gαq proteins restored plasma AVP in salt-
challenged DSS rats to levels observed prior to consuming a
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FIGURE 1 | Schematic representation of the major Gα protein signal transduction pathways activated following ligand binding at a G-protein coupled
receptor.
high salt diet (Wainford and Kapusta, 2010). Moreover, diuresis
stimulated by pharmacological or physiological manipulations
that are known to evoke this response exclusively or in part via
suppression of AVP release (Kondo et al., 1993; Kakiya et al.,
2000; Krowicki and Kapusta, 2006; Ruginsk et al., 2007) was
completely or partially restored (Wainford and Kapusta, 2010).
Therefore, the down-regulation of PVN Gαq proteins plays a
critical counter-regulatory role in preventing AVP hypersecretion
by reducing the ability of endogenous GPCR ligands to trigger
AVP release, and may represent a new therapeutic target in
pathophysiological states featuring AVP dysregulation (e.g.,
heart failure, salt-sensitive hypertension). However, the potential
impact of PVN Gαz/Gαq proteins in other pathophysiological
states featuring AVP excess remains to be determined and is not
the focus of the remainder of this review.
Our prior studies also established a role for brain Gαi/Gαo
proteins to mediate hypotension and bradycardia in response
to central activation of the NOP receptor (Wainford et al.,
2008), but did not determine which specific Gαi/Gαo protein
is responsible for the observed effects. To address this issue
and provide clarity as to the individual roles of brain Gαi/Gαo
proteins in cardiovascular regulation, conscious Sprague–Dawley
rats were administered gaunabenz, a selective α2-adrenoceptor
agonist (Degoute, 2007). The α2-adrenoceptor is intimately
involved in the central control of cardiovascular function
and fluid and electrolyte homeostasis (Ruffolo et al., 1991;
Nasman et al., 2001). In vitro studies have demonstrated that
immediately following post-ligand binding, α2-adrenoceptors
activate downstream Gαi(1–3), Gαo, and Gαs protein signal
transduction pathways (Remaury et al., 1993; Eason and Liggett,
1995). Ligand-binding at central α2-adrenoceptors in conscious
rats evokes bradycardia, hypotension, sympathoinhibition (Grisk
and Dibona, 1998; Huang and Leenen, 1998), diuresis and
natriuresis (Gellai and Edwards, 1988; Menegaz et al., 2001).
Using a highly targeted ODN approach to selectivity down-
regulate central Gαi1, Gαi2, Gαi3, Gαo, or Gαs proteins (Rossi
et al., 1995; Standifer et al., 1996; Silva et al., 2000; Hadjimarkou
et al., 2002), we determined that the hypotensive and natriuretic
responses to selective central α2-adrenoceptor activation are
abolished by Gαi2 down-regulation, or are converted to a
pressor response by Gαs down-regulation. We speculate these
responses reflect altered sympathetic outflow to multiple organ
systems (e.g., renal, splanchnic). In contrast, the profound
α2-agonist-stimulated bradycardia and diuresis was unaltered
by prior down-regulation of individual brain Gαi(1–3), Gαs,
or Gαo proteins (Wainford and Kapusta, 2012). These data
suggest potential redundancy of Gα protein pathways to regulate
heart rate. In light of our prior findings about AVP regulation
(described above), we speculate the diuretic response to central
α2-adrenoceptor activation is regulated by Gαz/Gαq due to
a significant component of this response being mediated by
suppression of AVP release (Brooks et al., 1986; Cabral et al.,
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1998). Together, these studies provide new insight into the
intracellular mechanism of action of brain α2-adrenoceptors
in vivo and document that the physiological responses evoked
by receptor activation are greatly influenced by the availability
and/or brain protein expression levels of individual downstream
Gα proteins (Wainford and Kapusta, 2012). Further, these data
provide compelling in vivo support for the pharmacological
paradigm of functional selectivity (Patel et al., 2010) as predicted
from in vitro studies and mathematical models (Nasman et al.,
2001; Hein, 2006).
Brain Gαi2 Proteins and Acute
Physiological GPCR Activation
Maintenance of fluid and electrolyte homeostasis in response to
acute increases in sodium intake occurs via complex integrated
neural, humoral, and hemodynamic pathways to regulate the
renal excretion of sodium. If these endogenous pathways
are impaired, salt-sensitive hypertension can develop. A key
component of the renal handling of sodium and water, and thus
blood pressure, in response to alterations in plasma sodium,
is the regulation of sympathetic outflow and renal sympathetic
nerve traffic (Guyton, 1991; Lohmeier et al., 1999; DiBona,
2004, 2005; May et al., 2009), which is directly influenced
by multiple brain GPCR systems (e.g., the α2-adrenoreceptor)
(Ruffolo et al., 1991; Nasman et al., 2001). However, the central
mechanisms regulating sympathetic outflow (global and renal
specific) to facilitate natriuresis during elevations in plasma
sodium content remain unclear (DiBona, 2005; Kompanowska-
Jezierska et al., 2008; Bie, 2009). Consequently, we elected
to examine the role of endogenous brain Gαi2 protein-gated
signal transduction pathways in mediating the sympathetic
and natriuretic responses to acute physiological challenges [i.v.
volume expansion (VE) and i.v. sodium load] that impact
the renal handling of sodium, in part, by suppressing central
sympathetic outflow (Haselton et al., 1994; Kapusta and Obih,
1995; DiBona and Kopp, 1997; Singer et al., 1998; Manunta et al.,
2011). Selective ODN-mediated down-regulation of brain Gαi2
proteins (1) abolished the renal sympathoinhibitory response
and attenuated the natriuresis to VE (Kapusta et al., 2012)
and (2) abolished the global sympathoinhibitory response and
attenuated the natriuresis to a 1M sodium load (Wainford
et al., 2013) via a mechanism requiring intact renal sympathetic
nerves. Demonstrating the central nature of this effect, it is
notable that kidney function was maintained following down-
regulation of brain Gαi2 proteins, as demonstrated by the
natriuretic and diuretic responses to i.v. bolus administration
of furosemide in Gαi2 ODN-treated rats (Kapusta et al.,
2012). The results generated from these physiological studies
demonstrate that central Gαi2 proteins are involved in mediating
the renal excretory responses to these acute challenges to sodium
homeostasis via an inhibitory influence on sympathetic outflow,
specifically renal sympathetic nerve activity. This conclusion
is supported by evidence that down-regulation of brain Gαi2
proteins prevented the suppression of global sympathetic outflow
[assessed by circulating norepinephrine (NE) levels] during a
sodium load (Wainford et al., 2013). Moreover, in rats implanted
with a renal nerve recording electrode, brain Gαi2 protein
down-regulation abolished isotonic saline volume expansion
(5% body weight) evoked suppression of renal sympathetic
nerve activity (Kapusta et al., 2012). Bilateral renal denervation
to remove the influence of the renal sympathetic nerves on
kidney function prevented Gαi2 protein down-regulation from
altering the natriuretic response to either the i.v. VE or 1M
sodium load (Kapusta et al., 2012; Wainford et al., 2013).
Linking our data generated following acute exogenous central
GPCR activation (described above) to these physiological studies
provides evidence that central α2-adrenoceptors are the principal
brain GPCR involved in producing renal sympathoinhibition,
and consequently natriuresis, in response to acute VE (Patel,
1991). Therefore, we postulate that endogenous α2-adrenoceptor
mediated activation of brain Gαi2 protein-gated pathways
represents a key mechanism by which sympathoinhibition and
natriuresis occurs in vivo in response to acute challenges to
sodium homeostasis. Collectively, these data report a central
molecular mechanism that plays a key role in modulating
the level of central sympathetic outflow, blood pressure, and
natriuresis in response to acute pharmacological or physiological
stimuli (Figure 2). Further, these data establish that central
Gαi2 proteins impact sympathetic outflow predominantly via
regulation of the renal sympathetic nerves. The present studies
extend our knowledge of the CNS regulatory mechanisms
influencing the kidney to maintain sodium homeostasis.
Given the intimate association between fluid and electrolyte
homeostasis and the long-term control of arterial pressure, we
speculate that Gαi2-protein mediated suppression of central
sympathetic outflow may represent a new component in
integrated autonomic regulatory processes that govern the
long-term regulation of systemic arterial blood pressure. The
importance of enhancing our understanding of the underlying
cellular signaling pathways involved in the neural control
of sodium excretion in health and disease is highlighted
by the multiple pathophysiological disease states that exhibit
sodium retention, including heart failure and certain models
of hypertension, particularly salt-sensitive hypertension (Bayorh
et al., 1998; Lastra et al., 2010).
Brain Gαi2 Proteins and Salt-resistance
Due to the dramatic impact of hypertension on human health and
the prevalence of salt-sensitive hypertension in approximately
50% of hypertensive patients (Meneton et al., 2005; Franco and
Oparil, 2006; Whelton et al., 2012; Kotchen et al., 2013), we
elected to study the potential role of central Gαi2 proteins in
the pathophysiology of salt-sensitive hypertension. It is well
established in normotensive salt-resistant subjects that neural
(renal sympathetic) and humoral (angiotensin-aldosterone)
sodium-retaining mechanisms are suppressed to counter the
influence of dietary salt-intake on central sympathetic outflow
and systemic cardiovascular hemodynamics (Lohmeier et al.,
1999; Brooks et al., 2005; Osborn et al., 2008). Consequently,
we examined the role of central Gαi2 proteins in facilitating
sodium homeostasis during a 7-day dietary sodium restriction
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FIGURE 2 | Schematic representation of the functional selectivity
of G-protein coupled receptor activated Gα protein signal
transduction pathways in mediating the physiological responses
evoked by central exogenous administration of N/OFQ and
Guanbenz or the physiological stimuli of an iv volume
expansion or sodium load. AVP, vasopressin; NE, Norepinephrine;
NOP, nociceptin/orphanin FQ receptor; RSNA, renal sympathetic nerve
activity.
or supplementation in the Sprague–Dawley rat. In control
scrambled ODN-treated rats, 7-days of altered dietary sodium
intake did not alter blood pressure and evoked a site-specific
PVN decrease (sodium deficiency) or increase (sodium excess) in
PVNGαi2 proteins (Kapusta et al., 2012). The sodium-stimulated
changes in Gαi2 protein expression were restricted to the PVN
and did not occur in other hypothalamic regions (e.g., SON,
posterior hypothalamus). Further, dietary sodium restriction or
excess did not alter expression levels of Gαi1, Gαi3, or Gαo
proteins in any brain site examined. The observation of sodium-
evoked site and subunit-specific changes in PVN Gαi2 protein
expression is of considerable pathophysiological interest as this
brain site plays a key role in responding to alterations in body
fluid sodium concentration/osmolality (Toney et al., 2003) and
the central control of sympathetic outflow, sodium homeostasis,
and blood pressure (Leenen et al., 2002; Kenney et al., 2003; He
et al., 2005; Carmichael and Wainford, 2015). In rats adapted
to a high-sodium diet (0.9% NaCl drinking water), acute ODN-
mediated down-regulation of central Gαi2 proteins resulted in
the development of sodium retention, global sympathoexcitation
(i.e., increased circulating NE), and moderately elevated blood
pressure. These findings provide further support for the long
established Guytonion hypothesis of the intimate connection
between fluid and electrolyte homeostasis and the long-term
regulation of blood pressure (Guyton, 1991). Additionally, in
accordance with recent hypotheses (Rodriguez-Iturbe and Vaziri,
2007; Fujita and Fujita, 2013; Stocker et al., 2013), our data
indicate that enhanced central sympathetic outflow plays a role
in these regulatory processes. The PVN as a potential locus of
Gαi2protein mediated regulation of sympathetic outflow is not
unexpected, due to the critical role of the PVN in mediating
sympathoinhibition (Coote, 1995; Akine et al., 2003; Frithiof
et al., 2009), particularly in response to increased plasma and/or
cerebrospinal fluid sodium in salt-resistant subjects (Brooks et al.,
2005; DiBona, 2005; He et al., 2005). These data demonstrate
that PVN Gαi2 protein pathways play a role in maintaining fluid
and electrolyte balance during alterations in sodium intake by
controlling the influence of the sympathetic nervous system on
natriuresis and suggest a role for these proteins in long-term
blood pressure regulation (Kapusta et al., 2012).
Currently, the central molecular mechanisms that mediate
sympathoinhibition in response to excess dietary sodium intake
as found in the typical western diet [Center for Disease
Control and Prevention (CDC), 2010] remain to be fully
elucidated. Based on our prior observations, we hypothesized
that in salt-resistant phenotypes (e.g., Sprague–Dawley rat)
subjected to a chronic elevation in dietary sodium intake,
brain Gαi2 protein signaling pathways will be augmented to
maximize inhibition of central sympathetic outflow to the
kidneys via the renal sympathetic nerves and thereby facilitate
sodium excretion. Further, we predict that blockade of this
central Gαi2 protein sympathoinhibitory pathway will trigger
sodium and water retention and the development of salt-
sensitive hypertension. To chronically down-regulate central
Gαi2 proteins, our acute ODN administration protocol was
adapted to utilize an alzet osmotic minipump connected to
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an indwelling i.c.v. cannula to deliver a continuous infusion
of a control scrambled or Gαi2 ODN (Kapusta et al., 2013).
During ODN infusion, naïve or previously bilaterally renal
denervated male Sprague–Dawley rats were randomly assigned
to receive a normal salt (0.4%) or high-salt (8.0%) diet for
21-days. In control scrambled ODN-infused rats, salt-loading
which did not alter blood pressure, evoked a site-specific increase
in hypothalamic paraventricular nucleus (PVN) Gαi2 protein
levels and suppression of circulating norepinephrine content and
plasma renin activity. To demonstrate the functional significance
of sodium-evoked PVN specific increase in Gαi2 proteins, we
examined how chronic ODN-mediated down-regulation of brain
Gαi2 protein levels impacted blood pressure and neural/humoral
sodium retaining mechanisms during high salt intake. In these
studies, salt-loaded rats continuously infused i.c.v. with a Gαi2
ODN developed salt-sensitive hypertension (Kapusta et al.,
2013). The development of salt-sensitive hypertension, featuring
an impaired pressure-natriuresis response, during CNS Gαi2
protein down-regulation involves global sympathoexcitation
that we postulate contributes to increased systemic arterial
pressure over time through (1) increased vascular contractility
and (2) enhanced renal tubular sodium reabsorption (DiBona
and Kopp, 1997; Lohmeier et al., 1999). In contrast to an
inhibitory influence on sympathetic activity and NE release,
Gαi2 protein pathways do not impact the suppression of the
renin-angiotensin system (as assessed by reduced plasma renin
activity) during chronic increases in dietary sodium intake
(Kapusta et al., 2013). In separate studies using the technique of
chronic bilateral renal denervation, which remove the influence
of the renal sympathetic nerves on kidney function, we were
able to prevent the development of central Gαi2 ODN-induced
salt-sensitive hypertension. In renal denervated animals, we
did not observe global sympathoexcitation or resetting of the
chronic pressure-natriuresis curve in response to elevated in
dietary sodium intake (Wainford et al., 2013). These data
demonstrate the physiological importance of PVN Gαi2 proteins
as a sodium-activated “anti-hypertensive” central pathway which
regulates the renal handling of sodium via the renal sympathetic
nerves to prevent the development of salt-sensitive hypertension
(Figure 3). Our findings support the inclusion of a role for
enhanced central sympathetic outflow in the current modeling
of the pathophysiology of hypertension that is based on the
classical Guytonian theory of pressure natriuresis (Guyton,
1991). Further, our data highlight central Gαi2 proteins as
a candidate mechanism that facilitates the communication
between the central nervous system and the kidneys to maintain
long-term blood pressure regulation.
Brain Gαi2 Proteins and Salt-sensitivity
Among multiple proposed mechanisms, impaired sympathetic
nervous system activity has been hypothesized to play a critical
role in the development of salt-sensitive hypertension (Brooks
et al., 2005; Osborn et al., 2009; Fujita and Fujita, 2013), a theory
gaining traction following reports of increased sympathetic
nervous system activity in animal models of salt-sensitive
hypertension (Kandlikar and Fink, 2011; Foss et al., 2013) and
salt-sensitive humans (Yatabe et al., 2010). Further, increasing
attention is focusing on the role of the renal sympathetic
nerves in blood pressure regulation following reports that renal
nerve ablation attenuates hypertension in human subjects (Esler
et al., 2012; Krum et al., 2014). Despite these recent advances,
it is widely acknowledged that the central nervous system
mechanisms that modulate central sympathetic outflow to the
kidney to facilitate sodium homeostasis and blood pressure
regulation require further investigation (Brooks et al., 2005;
Ellison and Brooks, 2011; Stocker et al., 2013). Based on our
prior findings, generated solely in the Sprague–Dawley rat
phenotype, we hypothesized that increased dietary sodium intake
upregulates PVN Gαi2 proteins to suppress central sympathetic
outflow, particularly to the kidneys, to maintain fluid and
electrolyte balance and normotension in multiple salt-resistant
phenotypes. Extending this hypothesis, we predicted that failure
to up-regulate PVN Gαi2 proteins in response to increased
salt intake contributes to the pathophysiology of salt-sensitive
hypertension.
Utilizing the Dahl rat phenotypes as an established model
of salt-resistance vs. salt-sensitivity, we observed that high
dietary sodium intake evoked a site-specific up-regulation of
PVN Gαi2 protein levels in the DSR and Brown Norway rat
phenotypes (Wainford et al., 2015). These findings extend our
prior studies in Sprague–Dawley rats (Kapusta et al., 2012,
2013) and demonstrate that PVN Gαi2 protein up-regulation
in response to increased salt-intake occurs in multiple rat
phenotypes that exhibit salt-resistance. In contrast, in the DSS
rat, which developed salt-sensitive hypertension, there was a
failure to up-regulate PVN Gαi2 proteins (Wainford et al.,
2015). This difference would suggest a molecular mechanism
that contributes to DSS rat hypertension. During high salt-
intake, central ODN-mediated Gαi2 protein down-regulation
evoked sympathetically mediated salt-sensitive hypertension in
the DSR rat and exacerbated the magnitude of salt-sensitive
hypertension observed in the DSS phenotype. As determined
via radiotelemetry, down-regulation of CNSGαi2proteins evoked
an elevation in blood pressure in the DSR rat upon high-
salt challenge of approximately 20mmHg in a 3-day period,
followed by a prolonged and persistent increase in blood
pressure over time. In the DSS rat, CNS Gαi2protein down-
regulation also evoked an enhanced pressor response to salt-
intake, after which the rate of development of hypertension was
comparable between scrambled and Gαi2 treated animals. This
rapid elevation in blood pressure following salt-intake and brain
Gαi2protein down-regulation reflects a reduction in the slope of
the blood pressure-sodium excretion relationship, indicative of
increased short-term salt-sensitivity of blood pressure (Wainford
et al., 2015). This would reset the pressure-natriuresis set-
point to a higher level within several days, as observed in the
current studies, and as hypothesized by current models of the
development of salt-sensitive hypertension (Van Vliet et al., 2006;
McLoone et al., 2009; Fujita and Fujita, 2013).
Chronic removal of the influence of the renal sympathetic
nerves abolished central Gαi2 ODN-induced sympathetically
mediated salt-sensitive hypertension in DSR rats and attenuated
the development of salt-sensitive hypertension in DSS rats. These
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FIGURE 3 | Schematic representation of the differential impact of
elevated dietary sodium intake on PVN Gαi2 protein expression and
the consequences of this on central sympathetic outflow, sodium
homeostasis, and blood pressure in salt-resistant vs. salt-sensitive
phenotypes. MAP, mean arterial pressure; NE, Norepinephrine; PVN,
paraventricular nucleus.
data support a direct role of renal sympathetic innervation of
the kidney in the development of salt-sensitive hypertension
(Wainford et al., 2015). Based on our prior studies, we
speculate in intact animals in which the influence of brain
Gαi2 was removed, there was a failure to suppress sympathetic
outflow to the kidneys. This would have the consequence of
increasing both renal NE release and NE-mediated sodium
reabsorption leading to the observed sodium retention to
drive the pathophysiology of salt-sensitivity. To confirm that
impaired up-regulation of central Gαi2 proteins impacts salt-
sensitivity in the DSS rat, we conducted studies using an 8-
congenic DSS rat, which has chromosome 8 encoding the
GNAI2 gene from the Brown Norway rat (Mattson et al., 2008).
During high salt-intake, the 8-congenic DSS rat exhibited up-
regulation of PVNGαi2 proteins as well as attenuation of sodium
evoked hypertension, sodium retention and sympathoexcitation
(Wainford et al., 2015). As anticipated, because of the
multifactorial nature of DSS hypertension, restoration of sodium-
stimulated PVN Gαi2 protein up-regulation attenuated, but
did not abolish, the hypertension. Collectively, these studies
report that sodium evoked up-regulation of PVN Gαi2 proteins
represents a conserved central molecular mechanism that is
required to suppress renal sympathetic outflow to maintain
sodium homeostasis and normotension in multiple salt-resistant
rat phenotypes. Additionally, studies conducted in the DSS
and 8-congenic DSS rat provide the first direct evidence
that impairment of PVN Gαi2 signal transduction pathways
contributes to the pathophysiology of salt-sensitive hypertension
(Figure 3).
Future Directions and Significance
Despite the insight our recent studies have provided over the
last several years into the impact of central Gαi2proteins on
the salt-sensitivity of blood pressure, several questions remain
to be addressed. A critical issue remains the time course of
up-regulation of hypothalamic PVN Gαi2 proteins in response
to increases in dietary sodium intake. At present, all data
generated by our laboratory represents end-point assessment
after 21-days of increased dietary intake (Kapusta et al., 2013;
Wainford et al., 2015). Our physiological data suggests up-
regulation of Gαi2 proteins is an early event but this is yet to
be confirmed. Further, identification of the mechanism driving
the increased expression of hypothalamic PVN Gαi2 proteins
in response to altered dietary sodium intake remains to be
established. Despite our failure to detect changes in either
plasma sodium or osmolality in SD, DSR, or Brown Norway
rats during increased sodium intake in end-point measurements
made on day-21 of high salt-intake (Kapusta et al., 2013;
Wainford et al., 2015), we speculate minute changes in plasma
sodium/osmolality following sodium ingestion (i.e., after a
meal) are sensed by osmoreceptor/sodium-sensitive receptors
located in the hypothalamic PVN, the circumventricular organs
(Brooks et al., 2005; Stocker et al., 2013) or the renal afferent
nerve terminals (DiBona and Kopp, 1997) and trigger the
observed alterations in protein expression. An alternative
potential mechanism driving the increase in PVN Gαi2 protein
expression during salt intake may be sodium-evoked alterations
in PVN neurotransmitter release (e.g., altered intra-PVN levels
of glutamate and/or GABA) and that the complex inhibitory and
excitatory actions evoked by these neurotransmitters may evoke
altered PVN Gαi2 levels.The current studies strongly suggest
the PVN as the locus of the observed actions of central Gαi2
proteins, however future microinjection studies, designed to
down-regulate Gαi2 proteins site-specifically within the PVN
are required to definitively establish the PVN as a brain site in
which Gαi2 protein pathways act to produce sympathoinhibitory
influences on the renal handling of sodium and water to
counter the development of salt-sensitive hypertension. We
speculate, given the profound impact of alterations in PVN
Gαi2 on sympathetic outflow, that the observed changes in
Gαi2 expression in response to increased salt intake occur
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in the parvocellular sympathetic-regulatory neurons, not the
magnocellular neurons. An additional issue not addressed by our
current work is the cellular mechanism(s) by which central Gαi2
proteins modulate sympathetic outflow, sodium homeostasis,
and blood pressure. We postulate that central Gαi2 proteins
influence these physiological parameters through alteration of
neuronal firing patterns, via actions to inhibit adenylate cyclase
activity and/or Ca2+ channels in sympathetic neurons, to evoke
changes in the activity of the CNS to impact central sympathetic
outflow. However, electrophysiological recordings conducted
in conscious animals and in brain slice preparation studies
are required to establish the underlying cellular mechanisms
involved in these responses.
Our observation of an increase in PVN Gαi2 protein
expression in multiple salt-resistant rat phenotypes in response
to elevated sodium intake, and the absence of this response
in the DSS rat, is of high physiological significance because of
the pivotal role that the PVN plays in the neural network that
influences sympathetic outflow and blood pressure regulation.
Debate exists regarding the underlying cause of salt-sensitive
hypertension, which could result from either over-activity of the
sympathetic nervous system (Osborn et al., 2009) or excessive
salt reabsorption at the level of the kidneys (Montani and Van
Vliet, 2009). Our studies, as well as those of Mu et al. (2011);
Mu et al., suggest that the underlying pathogenesis of salt-
sensitive hypertension involves integration of both the central
nervous system and the kidneys and we demonstrate that this
communication is regulated by the renal sympathetic nerves
via a CNS Gαi2 protein pathway. The potential translational
impact of our findings of a role of Gαi2 proteins in blood
pressure regulation is suggested by reports of single nucleotide
polymorphisms (SNPs) in the human GNAI2 gene. SNPs in the
GNAI2 gene are associated with increased hypertension risk in
Caucasian Italians and in the Millennium Genome Project for
Hypertension in Japan (Menzaghi et al., 2006; Kohara et al.,
2008), providing the first evidence of the potential utility of
GNAI2 SNPs as a biomarker of hypertension risk. However, at
present the association between human GNAI2 SNPs and the
salt-sensitivity of blood pressure remains to be investigated. Our
findings of a direct role of the renal sympathetic nerves in the
pathophysiology of salt-sensitive hypertension provides renewed
support for the decades of evidence that have documented a
role of the renal sympathetic nerves in the pathogenesis of
hypertension in multiple animal models (DiBona and Esler,
2010) and in human hypertension (Schlaich et al., 2009). The
potential clinical applicability of these data is provided by the
recent renal denervation studies in humans that have resulted
in a persistent reduction in blood pressure (Esler et al., 2012;
Krum et al., 2014). We acknowledge that the clinical efficacy of
renal nerve ablation in resistant hypertensive patients remains
to be definitively established following recent studies, which
failed to report reduced blood pressure in resistant hypertensive
patients (Bhatt et al., 2014; Bakris et al., 2015). However, based
upon the successful renal ablation trials, it has been speculated
that the success of this clinical procedure reflects, in part,
reduced hypothalamic-mediated sympathetic outflow (DiBona
and Esler, 2010)—a hypothesis congruent with our current
data. Collectively, our data suggest a novel molecular/cellular
target (brain Gαi2 proteins) at which new therapies can
be directed to alter systemic cardiovascular parameters (e.g.,
antihypertensive medications) and/or renal excretory function
(natriuretic compounds) to treat the multiple disease states that
feature sympathoexcitation and the impaired renal handling of
sodium, such as salt-sensitive hypertension or congestive heart
failure.
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